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Robust	 inflammatory	 responses	 are	 critical	 to	 survival	 following	 respiratory	












EZH2	are	 likely	to	 impair	mucosal	 immunity;	however,	 they	may	prove	useful	
for	conditions	driven	by	pulmonary	neutrophil	influx,	such	as	adult	respiratory	
distress	syndrome.
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1 	 | 	 INTRODUCTION
Macrophages	 are	 widely	 distributed	 through	 vertebrate	
tissues	and	play	essential	roles	in	homeostasis,	and	in	re-




atherosclerosis.1-	3	 Activation	 of	 macrophages	 is	 critical	









proteins,	 activate	 signaling	cascades	 to	 induce	a	 cellular	
response.	Multiple	TLRs,	through	MyD88-	dependent,	and	










its	 trans-	differentiation.	 EZH2	 has	 been	 intensely	 studied	
in	cancer,6,7	and	has	gained	attention	in	generating	a	func-
tional,	 adaptive	 immune	 response.8,9	 Macrophage	 switch-
ing	 between	 functional	 states	 has	 been	 identified	 to	 be	
dependent	on	reversible	trimethylation	of	histone	H3K27.10
Several	recent	studies	have	employed	genetic	targeting	
of	 EZH2	 or	 pharmacological	 EZH2-	selective	 inhibitors	
to	demonstrate	an	important	role	in	the	regulation	of	in-
flammatory	responses.	These	 investigations	have	yielded	





immune	 diseases	 including	 experimental	 autoimmune	
encephalomyelitis	and	colitis.	In	this	latter	study,	loss	of	










neutrophil	 migratory	 capacity.	 This	 dichotomy	 of	
action	 may	 also	 explain	 the	 apparent	 contradictory	
outcomes	of	earlier	studies	of	 the	role	of	EZH2	in	 in-






2 	 | 	 MATERIALS AND METHODS
2.1	 |	 Animal studies
All	experimental	procedures	were	carried	out	 in	accord-
ance	 with	 the	 Animals	 (Scientific	 Procedures)	 Act	 of	
1986.	 Male	 C57BL/6J	 mice	 aged	 8-	12  weeks	 were	 pur-
chased	 from	 Harlan	 Laboratories,	 UK	 Ezh2flox/flox	
mice	possessing	 loxP	sites	upstream	and	downstream	of	
the	 2.7	 kb	 SET	 domain	 and	 were	 a	 gift	 from	 Alexander	
Tarakhovsky	 (Rockefeller,	 New	 York).	 These	 mice	 were	
bred	with	LysMcre/+,	 a	cre	 recombinase	under	 the	con-
trol	of	lysozyme	M,	to	target	Ezh2	for	deletion	in	myeloid	
cells,	 including	macrophages	and	neutrophils.	Offspring	
produced	 were	 either	 Ezh2flox/flox	 with	 no	 LysM- cre	
present,	 these	mice	acted	as	 littermate	controls,	or	were	
positive	 for	 the	 cre	 driver.	 For	 all	 in	 vivo	 experiments,	
conditional	 targeted	 cre	 positive	 mice	 were	 sex	 and	 age	
matched	 with	 floxed/floxed	 littermate	 controls;	 females	
aged	 10-	14  weeks	 were	 used	 for	 in	 vivo	 pneumococcal	
experiments.
In	order	to	genotype	these	mice	and	elucidate	the	cor-









were	 genotyped	 using	 the	 GoTaq	 Hot	 Start	 Polymerase	
(Promega).	The	PCR	product	produced	using	these	prim-
ers	was	run	on	a	2%	agarose	gel	at	45	volts	for	3	hours	and	
mice	homozygous	 for	 the	 loxP	sites	presented	a	band	at	
731	bp	and	those	wild	type	for	loxP	expression	with	a	band	
at	691	bp.	Mice	homozygous	for	the	flox	were	selected	and	

























2.2	 |	 Bone marrow- derived macrophages 
(BMDM)
C57BL/6	 mice	 were	 obtained	 and	 sacrificed	 via	 cervical	
dislocation.	The	hind	legs	were	removed,	the	muscle	and	
skin	dislodged	using	gauze	and	to	clean	the	bone	before	
being	 placed	 in	 ice	 cold	 sterile	 Dulbecco's	 phosphate-	
buffered	 saline	 (PBS),	 and	 this	 procedure	 was	 repeated	
with	the	fore	legs.	The	bones	were	then	placed	in	ice-	cold	
DMEM	(Sigma)	with	10%	fetal	bovine	serum	(FBS)	(Life	
technologies)	 and	 1%	 penicillin/streptomycin	 (Sigma)	
in	a	primary	 tissue	culture	hood.	The	ends	of	 the	bones	
were	 removed	 and	 a	 17-	gauge	 needle	 was	 used	 to	 flush	
out	the	bone	marrow	using	the	culture	media.	The	bone	
marrow	 was	 disrupted	 and	 centrifuged	 at	 1600	 rpm	 for	
6  minutes	 and	 the	 supernatant	 removed.	 Cells	 were	 re-
suspended	 in	 5-	mL	 culture	 medium	 plus	 macrophage	
colony-	stimulating	 factor	 (M-	CSF)	 (Affymetrix	 eBiosci-











was	 then	centrifuged	at	200	G	 for	5 minutes	at	4℃	 and	
the	 cells	 resuspended	 in	 DMEM/10%	 FBS/1%penicillin/
streptomycin.	 Cells	 were	 then	 counted	 and	 plated	 at	 a	
concentration	of	1	×	106/mL	in	6-	well	plates	for	24	hours.	








age)	 fluid	 (PBS,	 1%	 FBS/0.5	 mM	 EDTA).	 BAL	 fluid	 was	




24-	well	plates	and	cells	were	 left	 to	adhere	 for	24	hours	
before	 the	 removal	 of	 non-	adherent	 cells	 by	 washing	 in	
pre-	warmed	(37℃)	DMEM.	The	remaining	adherent	cells	
were	termed	AMs.




was	 incubated	 on	 ice	 for	 15  minutes.	 Mouse	 neutrophil	
enrichment	 cocktail	 (EasySep)	 containing	 primary	 an-
tibodies	 against	 non-	neutrophils	 was	 added	 at	 100	 μL/





in	 a	 magnetic	 field	 for	 2  minutes	 at	 room	 temperature	
and	 the	 remaining	 PBS	 containing	 the	 neutrophils	 was	
removed.
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2.6	 |	 Adoptive transfer
Neutrophils	were	 isolated,	as	described	above,	 from	PEP3	
mice	that	possess	a	naturally	occurring	CD45.1	isoform	as	




2.7	 |	 Intraperitoneal LPS






















blunt	 dissection	 and	 a	 23-	gauge	 needle,	 connected	 to	 a	
1-	mL	syringe	filled	with	BAL	fluid,	was	inserted	into	the	
trachea.	The	BAL	fluid	was	then	forced	into	the	lungs	by	
pressure	 and	 was	 left	 for	 1  minute.	 BAL	 fluid	 was	 then	
extracted	from	the	lungs	and	then	fluid	was	placed	in	an	
Eppendorf	on	ice.
2.10	 |	 Cell counting
Cells	 were	 pelleted	 after	 in	 vivo	 experiments	 and	 were	
resuspended	 in	 1	 mL	 PBS.	 Acridine	 Orange	 provides	 a	
total	cell	count	while	DAPI	provided	information	on	the	
total	number	of	dead	cells	allowing	the	calculation	of	vi-
ability	 of	 each	 sample	 using	 NucleoView	 software	 for	
Nucleocounter.
2.11	 |	 Exposure to S pneumoniae
S pneumoniae	 strain	 D39	 (National	 collection	 of	 Type	
Cultures	7466)	was	prepared	in	Todd	Hewitt	Broth	(Sigma)	
and	 incubated	 at	 37℃	 5%	 CO2	 until	 an	 optical	 density	 of	
OD600	 was	 achieved	 from	 10	 mL	 of	 growth	 media.	 Mice	




units	 of	 D39.	 Mice	 were	 closely	 monitored	 and	 weighed	
every	12	hours	to	assess	health	(a	threshold	of	20%	weight	








2.12	 |	 Culture of S pneumoniae




of	20	μL	of	 the	 serial	dilution	of	blood	or	 lung	digest	was	













2.13	 |	 Lung digestion
The	left	lobe	of	the	lung	was	placed	into	a	bijou	containing	
ice-	cold	DMEM	during	the	cull.	DMEM	was	removed	and	





incubator	at	37℃	 for	30 minutes.	To	 stop	 the	digestion,	
0.005	 mM	 EDTA	 in	 DMEM	 was	 added	 to	 the	 digestion	
media	in	an	equal	volume.	The	digestion	was	then	forced	
through	a	70-	µm	culture	sieve.	At	this	point,	samples	re-
quired	 for	 S pneumoniae	 infection	 analysis	 were	 taken	
and	placed	on	blood	agar	plates.
2.14	 |	 RNA extraction from tissue
RNA	 was	 isolated	 from	 tissues	 using	 Trizol	 reagent	
(Sigma).
2.15	 |	 RNA analysis
RNA	 was	 isolated	 from	 cells	 using	 the	 RNeasy	 mini	 kit	
(Qiagen).





2.17	 |	 Quantitative real- time PCR 
(qPCR)
cDNA	was	analyzed	in	96-	well	MicroAmp	optical	reaction	
plates	 (Life	 Technologies).	 All	 reactions	 were	 performed	









2.18	 |	 Histone purification
Histones	 were	 purified	 from	 cells	 by	 growing	 mac-
rophages	 to	 a	 density	 of	 3	 ×	 107	 (Active	 Motif	 -	 40025).	
Histone	H3K27me3	conversion	was	measured	using	 the	
Active	 Motif	 kit	 (Epiquik	 Histone	 Methyltransferase	 ac-
tivity	assay	kit	(P-	3005)).
2.19	 |	 MTT viability assay
Cell	viability	after	treatment	with	EZH2	inhibitors	was	de-
termined	using	an	MTT	assay.
2.20	 |	 Enzyme- linked immunosorbent 
assay (ELISA)
The	 concentration	 of	 multiple	 proteins	 was	 determined	
using	 ELISA	 in	 a	 variety	 of	 samples	 including	 BAL,	 pe-




RNA	 was	 then	 run	 on	 a	 Nanostring	 nCounterTM	
(Nanostring	 Technologies)	 in	 conjunction	 with	 the	 pre-
made	 CodeSet	 called	 mouse	 inflammation	 panel	 V2	
(Nanostring	Technologies).
2.22	 |	 Transcription factor activation 
assays (TransAM)
RelA	 and	 IRF-	3	 transcription	 factor	 activation	 assays	
(Active	Motif)	were	carried	out	using	 the	 same	protocol	
with	the	only	difference	being	the	96-	well	plates	and	the	
antibodies	 used,	 each	 of	 which	 corresponding	 to	 the	 re-
spective	kit,	Rela:	40096,	IRF-	3:48396.
2.23	 |	 Pharmaceuticals
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2.24	 |	 Flow cytometry
1	×	106	cells	were	placed	in	a	96-	well	plate	and	cells	were	
suspended	in	50	μL	PBS	containing	Zombie	UV	live:	dead	
stain	 at	 1:2000	 (Biolegned)	 for	 15  minutes	 in	 the	 dark	
at	 RT.	 Live:	 dead	 staining	 was	 halted	 by	 adding	 150	 μL	
FACS	buffer	(PBS/4%	FBS)	and	centrifuging	at	2000	rpm	
for	 2  minutes	 at	 4℃.	 Supernatant	 was	 flicked	 off	 and	
cells	were	washed	in	200	μL	FACs	buffer	and	centrifuged	











utes	 at	 RT	 in	 the	 dark.	 Plates	 were	 then	 washed	 three	






Fluorophore	 Antibody	 target	 Dilution	 factor	 FITC	
Ly6G	200	A647	MerTK-	Bio	100	AF700	Ly6C	200	APC/













sation,	 ArC	 reactive	 beads	 (Thermo	 Fischer)	 were	 used	
according	to	the	manufacturer's	instructions	with	1:2000	








tified	 as	 Ly6G-	,	 CD64+	 Siglec	 F-	 and	 Neutrophils	 were	
identified	as	Ly6G+	CD11b+.
2.25	 |	 Boyden chamber assay
A	 Neuro	 Probe	 AP48	 48-	well	 Boyden	 chamber	 (Neuro	
Probe)	was	used	for	all	assays.	The	chamber	was	prepared	
by	adding	26	μL	pre-	warmed	(37℃)	CXCL-	5	(0,	0.5,	50,	500	





















ous	 variables	 between	 more	 than	 two	 groups,	 ANOVA	
was	 used	 with	 Tukey's	 correction	 for	 multiple	 testing	
T A B L E  1 	 Flow	cytometry	antibody-	fluorophore	and	dilution	
used	for	primary	antibody	cocktail

















3 	 | 	 RESULTS
3.1	 |	 Deletion of Ezh2 increases 
inflammatory cytokine production in 
multiple macrophage lineages
We	 assessed	 the	 efficacy	 of	 genetic	 targeting,	 using	 cul-
tured	BMDMs	from	LysM- Ezh2fl/fl	(myeloid-	targeted)	mice	






Next,	we	generated	mice	 lacking	EZH2	 in	 the	macro-




gene	 expression	 revealed	 a	 complex	 interaction	 between	




particular,	 the	 responses	 of	 CXCL1	 (KC)	 were	 striking,	
















before	 analysis	 of	 a	 panel	 of	 LPS-	induced	 inflammatory	
genes.	Here	we	observed	that	either	genetic	loss	of	EZH2,	
or	pharmacological	 inhibition	with	UNC1999,	amplified	














responses.	 UNC1999	 significantly	 increased	 ccl2	 induc-
tion,	by	a	small	amount	in	the	Ezh2fl/fl	control	mice,	with	
no-	significant	impact	on	responses	of	iNOS	and	IL6.
3.2	 |	 Ezh2 deletion enhances RelA 
activation in response to TLR- 4 activation
To	 investigate	 the	 wider	 impact	 of	 Ezh2	 deletion	 on	 ex-
pression	 of	 immune-	related	 genes	 in	 BMDMs,	 we	 used	
a	 pre-	made	 CodeSet	 (Mouse	 inflammation	 panel	 V2	
NanostringTM)	 (Figure  2A,	 Table  S1).	 We	 saw	 that	 the	
major	 changes	 in	 gene	 expression	 were	 between	 the	
Ezh2fl/fl,	and	the	LysM- Ezh2	under	basal	conditions,	with	
LPS	 exposure	 of	 the	 cells	 exerting	 a	 dominant	 effect	 on	
the	gene	expression	profile	 (Figure 2A).	As	many	of	 the	
differentially	 regulated	 genes	 under	 basal	 conditions	
were	components	of	 the	TLR-	NFkB	system,	we	 targeted	
some	 examples	 (Figure  2B).	 The	 TLR	 signaling	 system	
employs	a	number	of	overlapping	elements	 (Figure 2C),	
and	so	 to	refine	 the	parts	of	 the	cascade	 functionally	af-
fected	 by	 EZH2,	 we	 used	 a	 TransAm	 assay,	 which	 uses	





(Figure  2D),	 thereby	 anchoring	 the	 gain	 of	 function	 to	
TLR4	action.
3.3	 |	 Targeted deletion of EZH2 in 
pulmonary macrophages provides 








get	 both	 macrophage	 and	 neutrophil	 populations,	 and	










cytometry	 revealed	 was	 caused	 by	 a	 significant	 increase	
in	 the	 number	 of	 neutrophils20	 (Figure  3A).	There	 were	




an	 intranasal	 delivered	 S pneumoniae	 infection	 model.	
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This	 is	 a	 prevalent	 bacterial	 pathogen,	 which	 expresses	
multiple	lipoproteins	capable	of	activating	TLR2,	and	also	
pneumolysin,	which	may	activate	TLR4,	as	well	as	driving	
tissue	 damage	 and	 so	 broadly	 activating	 innate	 immune	
























3.4	 |	 Ezh2 deletion in pulmonary 
epithelial cells does not affect 
influenza responses
We	 have	 previously	 shown	 that	 pulmonary	 bronchial	
epithelial	cells	play	a	sentinel	role	in	gating	TLR-	4	medi-
ated	 time-	of-	day	 responses	 to	LPS	and	 inflammatory	 re-
sponses,	 regulated	 by	 specific	 elements	 of	 the	 epithelial	
cell	 clockwork.16,21	 Since	 our	 data	 revealed	 a	 striking	 in	
















3.5	 |	 Neutrophil EZH2 is essential 
to confer protection against 
bacterial infection
Previous	 work	 has	 shown	 that	 EZH2	 is	 critical	 for	 neu-
trophil	extravasation.19	To	investigate	this	phenotype	fur-
ther	in	our	physiological	models,	we	tested	inflammatory	
responses	of	LysM- Ezh2fl/fl	mice.	 In	 this	model,	all	 types	
of	macrophage	and	neutrophil	cells	are	targeted.	Initially,	
we	 tested	 pulmonary	 inflammatory	 challenges	 to	 nebu-
lized	LPS	exposure.	BAL	analysis	at	+4	hours	revealed	a	





pression	 of	 the	 neutrophil	 chemoattractant	 CXCL5	 and	
the	monocyte	chemoattractant	CCL2.	This	revealed	an	in-
crease	in	CCL2	in	BAL	from	LysM- Ezh2fl/fl	mice	following	
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in	 the	context	of	bacterial	 infection,	we	exposed	LysM- 


















3.6	 |	 Defective neutrophil migration can 
















isoforms	 of	 the	 neutrophils	 between	 the	 LysM- Ezh2fl/fl	
and	Ezh2fl/fl	control	animals	(Figure 5E).	However,	all	the	
macrophages	were	CD45.2,	and	therefore	of	host	animal	





tranasal	 infection	 with	 S pneumoniae.	 Here,	 we	 noted	 a	





Further,	 BAL	 cell	 recovery	 after	 infection	 showed	 a	 sig-
nificant	 increase	 following	 neutrophil	 addback	 in	 both	
genotypes,	 with	 the	 LysM- Ezh2fl/fl	 mice	 showing	 an	 in-
crease	 to	 control	 levels	 of	 BAL	 neutrophils	 (Figure  5K).	








4 	 | 	 DISCUSSION
Regulation	 of	 innate	 immunity	 at	 mucosal	 surfaces	 is	
exquisitely	 sensitive	 to	 context,	 and	 requires	 interplay	
between	resident	immune	surveillance	cells,	notably	mac-
rophages,	 epithelial	 cells,	 and	 recruited	 neutrophils.16	
There	 has	 been	 interest	 in	 targeting	 epigenetic	 mecha-
nisms	to	regulate	the	function	of	some	hematopoietic	cell	
malignancies,	 especially	 using	 drugs	 against	 the	 poly-
comb	II	complex.17	In	addition,	reports	suggest	targeting	




We	 investigated	 the	 role	 of	 EZH2	 in	 pulmonary	 mu-
cosal	inflammation,	and	for	this	used	inflammatory	chal-
lenge	 models	 targeting	 the	 lung,	 including	 nebulized	








macrophages	 isolated	 from	 different	 compartments,	 we	
identified	 a	 gain	 in	 inflammatory	 response	 to	 canonical	
TLR	 activation.	We	 were	 able	 to	 show	 that	 the	 effect	 of	
the	EZH2	inhibitor	UNC1999,	a	SAM-	binding	site17	phar-
macological	 inhibitor,	 was	 entirely	 dependent	 on	 the	
presence	of	EZH2,	and	thus	confirmed	the	exquisite	spec-
ificity	of	the	tool	compound.	Our	findings	reveal	a	greater	
complexity	 in	 the	 macrophage	 responses	 dependent	 on	
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EZH2,	with	increased	late	responses,	and	impaired	early	
responses	compared	 to	previous	 reports.15	To	 investigate	
the	 basis	 for	 this	 change,	 we	 used	 a	 transcription	 factor	
activation	assay	and	identified	a	specific	impact	of	EZH2	
on	 the	TLR4	cascade,	with	no	 impact	on	 the	viral	TLR3	
response	such	that	EZH2	has	specific	and	selective	action	
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by	inhibiting	TLR4-	mediated	proinflammatory	pathways.	
This	 led	 us	 to	 hypothesize	 that	 the	 EZH2	 effect	 may	 be	
specific	to	particular	immune	stimuli,	with	such	specific-







responses	 as	 part	 of	 the	 output.	 Although	 the	 CX3CR1	
driver	 may	 also	 target	 NK	 cells	 and	 dendritic	 cells	 in	
the	 contact	 of	 acute	 bacterial	 infection,	 the	 primary	
drivers	 of	 response	 are	 macrophages	 and	 neutrophils.	
Using	 nebulized	 LPS,	 we	 saw	 a	 small	 increase	 in	 neu-
trophil	infiltration	resulting	from	EZH2	loss,	but	overall,	
the	 impact	 was	 surprisingly	 modest.	 However,	 LPS	 is	 a	
mimic	of	gram-	negative	bacterial	infection,	which	is	less	
prevalent	 in	the	lung.	So,	we	switched	to	infection	with	
the	 gram-	positive	 bacterium	 S pneumoniae,	 a	 prevalent	
pulmonary	pathogen	and	the	commonest	cause	of	com-
munity	 acquired	 pneumonia.	These	 studies	 identified	 a	
major	 gain	 in	 immune	 response,	 with	 animals	 bearing	
macrophage-	targeted	 Ezh2	 having	 complete	 protection	
from	 bacteremia	 (ie,	 an	 extension	 of	 the	 pneumococcal	
infection	to	the	bloodstream).	Antibacterial	gain	was	as-
sociated	with	increased	numbers	of	both	alveolar	and	in-









response	 to	 bacterial	 infection,	 we	 extended	 these	 stud-
ies	 to	 include	 the	 myeloid	 lineage	 more	 generally,	 as	 in	
the	 neutrophil	 population	 EZH2	 is	 reported	 to	 exert	 a	
nongenomic	role	in	cytoskeletal	function,	and	motility.19	
To	achieve	this,	we	used	the	LysM- cre	driver.	Now,	in	the	









bers	 likely	 results	 from	 apoptosis	 resulting	 from	 excess	
bacteria,	a	well-	characterized	response	to	bacterial	sepsis	
in	the	lung.23
In	 order	 to	 investigate	 the	 contribution	 of	 the	 neu-
trophil	 deficit	 to	 the	 aberrant	 pneumococcal	 response	
in	 LysM- Ezh2fl/fl	 targeted	 mice,	 we	 used	 a	 neutrophil-	
adoptive	 transfer	 approach,	 using	 tail	 vein	 injection	 of	
bone	 marrow-	sourced	 neutrophils	 from	 CD45.1+	 to	
both	 control,	 and	 LysM- Ezh2fl/fl	 animals.	 The	 origin	 of	
the	 immune	 cells	 was	 tracked	 by	 using	 variant	 CD45	
expression,	 and	 flow	 cytometry.	 There	 was	 a	 highly	 se-
lective	 acquisition	 of	 transferred	 neutrophils,	 with	 no	
monocytes	 or	 macrophages	 in	 both	 recipient	 genotypes.	
Transfused	CD45.1+	neutrophils	were	sufficient	to	restore	
the	antibacterial	response	in	the	LysM- cre	mice,	thus	con-
firming	 that	 the	 defect	 in	 neutrophil	 recruitment	 to	 the	
lung	 was	 the	 likely	 primary	 cause	 of	 the	 impaired	 anti-
bacterial	 response	 seen	 in	 the	 LysM-	cre-	directed	 EZH2	
deletion.	 A	 possible	 explanation	 for	 this	 may	 be	 protein	
methyltransferase-	mediated	 activity	 of	 EZH2	 on	 talin-	1	





vascular	 epithelium	 during	 inflammation,	 an	 effect	 also	
mimicked	by	treatment	with	an	EZH2	inhibitor.24
Bronchial	 epithelial	 cells	 are	 key	 effector	 cells	 in	 im-
munological	 responses	 to	 inflammatory	 challenge	 and	
pathogenic	 organisms,	 and	 our	 earlier	 work	 has	 iden-
tified	 a	 critical	 role	 in	 conferring	 time-	of-	day	 circadian	
responses	to	 inflammatory	challenge.16	However,	we	did	
not	discover	any	difference	in	neutrophilic	inflammatory	
responses	 in	 the	 epithelial	 EZH2-	null	 animals	 to	 either	









loss	 of	 EZH2	 function	 in	 neutrophils	 results	 in	 marked	
impairment	 of	 anti-	bacterial	 defense	 in	 the	 lung.	 Thus,	
loss	of	EZH2	in	myeloid-	lineage	cells	has	paradoxical	and	
complex	 effects,	 leading	 to	 an	 apparent	 in	 vivo	 gain	 of	
function	in	macrophage	cells,	but	defective	migration	and	
antibacterial	 responses	 of	 neutrophils.	 The	 implications	
of	 these	 studies	 need	 to	 be	 considered	 in	 the	 context	 of	
clinical	use	of	EZH2	inhibitors.	These	are	currently	under	
evaluation	 for	 the	 treatment	 of	 various	 cancers,	 but	 our	
study	suggests	caution	due	to	the	immune	consequences	
of	targeting	EZH2.	It	is	possible	that	the	inhibition	of	neu-
trophil	 migration	 resulting	 from	 EZH2	 inhibition	 may	
have	a	therapeutic	role	in	diseases	associated	with	excess	
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